Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus
Lucas Guillo
(1)
,
Pierre Delanaye
(2, 3)
,
Martin Flamant
(4, 5)
,
Lucile Figueres
(6)
,
Sabine Karam
(7)
,
Sandrine Lemoine
(8)
,
Alban Benezech
(9)
,
Anne-Laure Pelletier
(4)
,
Aurélien Amiot
(10, 11)
,
Bénédicte Caron
(12, 13)
,
Carmen Stefanescu
(14)
,
Gilles Boschetti
(15, 16)
,
Guillaume Bouguen
(17, 18)
,
Jean-Francois Rahier
(19)
,
Jean-Marc Gornet
(20)
,
Jean-Pierre Hugot
(21)
,
Joëlle Bonnet
(20)
,
Lucine Vuitton
(22)
,
Maria Nachury
(23, 24)
,
Mathias Vidon
(25)
,
Mathieu Uzzan
(14)
,
Mélanie Serrero
(1)
,
Nina Dib
(26)
,
Philippe Seksik
(27)
,
Xavier Hebuterne
(28)
,
Jean-Philippe Bertocchio
(29)
,
Christophe Mariat
(30)
,
Laurent Peyrin-Biroulet
(13, 12)
1
Hôpital Nord [CHU - APHM]
2 CHU Nîmes - Hôpital Universitaire Carémeau [Nîmes]
3 Université de Liège
4 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
5 CRI - Centre de Recherche Interdisciplinaire / Center for Research and Interdisciplinarity [Paris, France]
6 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
7 Saint George Hospital University Medical Center [UOB LIBAN]
8 Hôpital Edouard Herriot [CHU - HCL]
9 Centre Hospitalier Henri Duffaut (Avignon)
10 EC2M3 - Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375)
11 Groupe Henri Mondor-Albert Chenevier
12 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
13 Service d'Hépato-gastro-entérologie [CHRU Nancy]
14 Hôpital Beaujon [AP-HP]
15 CIRI - Centre International de Recherche en Infectiologie
16 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
17 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
18 NuMeCan - Nutrition, Métabolismes et Cancer
19 CHU UCL Namur
20 AP-HP - Hopital Saint-Louis [AP-HP]
21 AP-HP Hôpital universitaire Robert-Debré [Paris]
22 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
23 INFINITE - Institute for Translational Research in Inflammation - U 1286
24 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
25 CHI Créteil
26 HIFIH - Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques
27 CRSA - Centre de Recherche Saint-Antoine
28 CHU Nice - Centre Hospitalier Universitaire de Nice
29 CHU Pitié-Salpêtrière [AP-HP]
30 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
2 CHU Nîmes - Hôpital Universitaire Carémeau [Nîmes]
3 Université de Liège
4 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
5 CRI - Centre de Recherche Interdisciplinaire / Center for Research and Interdisciplinarity [Paris, France]
6 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
7 Saint George Hospital University Medical Center [UOB LIBAN]
8 Hôpital Edouard Herriot [CHU - HCL]
9 Centre Hospitalier Henri Duffaut (Avignon)
10 EC2M3 - Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375)
11 Groupe Henri Mondor-Albert Chenevier
12 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
13 Service d'Hépato-gastro-entérologie [CHRU Nancy]
14 Hôpital Beaujon [AP-HP]
15 CIRI - Centre International de Recherche en Infectiologie
16 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
17 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
18 NuMeCan - Nutrition, Métabolismes et Cancer
19 CHU UCL Namur
20 AP-HP - Hopital Saint-Louis [AP-HP]
21 AP-HP Hôpital universitaire Robert-Debré [Paris]
22 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
23 INFINITE - Institute for Translational Research in Inflammation - U 1286
24 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
25 CHI Créteil
26 HIFIH - Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques
27 CRSA - Centre de Recherche Saint-Antoine
28 CHU Nice - Centre Hospitalier Universitaire de Nice
29 CHU Pitié-Salpêtrière [AP-HP]
30 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
Lucas Guillo
- Fonction : Auteur
- PersonId : 1162840
- ORCID : 0000-0001-9024-8541
Pierre Delanaye
- Fonction : Auteur
- PersonId : 772089
- ORCID : 0000-0002-1480-5761
Lucile Figueres
- Fonction : Auteur
- PersonId : 1102613
Gilles Boschetti
- Fonction : Auteur
- PersonId : 1111135
Philippe Seksik
- Fonction : Auteur
- PersonId : 761210
- IdHAL : seksik-philippe
- ORCID : 0000-0003-3596-9893
- IdRef : 085638374
Christophe Mariat
- Fonction : Auteur
- PersonId : 1132275
- IdRef : 115875298
Laurent Peyrin-Biroulet
- Fonction : Auteur
- PersonId : 1111110
- ORCID : 0000-0003-2536-6618
- IdRef : 087640147
Résumé
BACKGROUND AND AIMS: Patients with inflammatory bowel diseases (IBD) are exposed to drug-related nephrotoxicity and kidney-related extra-intestinal manifestations (EIMs). Patients should be monitored but guidance is lacking in current international recommendations. The objective of the Kidney Function Monitoring in Inflammatory Bowel Disease (MONITORED) initiative was to achieve an expert consensus about monitoring kidney function in IBD. METHODS: A literature review was first conducted. Then, an expert consensus meeting, involving 28 attendees representing French-speaking gastroenterologists and nephrologists, was held as part of an academic initiative on May 28, 2021. An anonymous Delphi process was used to discuss and vote on statements. Agreement was defined as at least 75% of participants voting for any one statement. RESULTS: Experts reached consensus on 11 criteria for referral to the nephrologist. Concerning kidney function monitoring, participants unanimously validated the use of serum creatinine with estimation of the glomerular filtration rate via the MDRD or CKD-EPI equations. A blood ionogram and a urine sample with measurement of a protein-to-creatinine ratio were also broadly agreed validated. Experts recommended performing this monitoring at IBD diagnosis, prior introducing a new treatment, and annually for EIMs screening and evaluation of treatment tolerance. An evaluation 3 months after starting mesalamine and then every 6 months was felt necessary, while for biologics an annually monitoring was deemed sufficient. CONCLUSION: The MONITORED consensus proposed guidelines on how to monitor kidney function in IBD. These recommendations should be considered in clinical practice to preserve kidney function and ensure the best approach to our patients.